


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Higuchi et al. Examiner: Maryam Monshipouri  
Serial No. : 10/086,913 Group Art Unit: 1652  
Filed : March 1, 2002 Customer No. : 21003  
For : PREVENTION AND TREATMENT OF MYCOPLASMA-  
ASSOCIATED DISEASES

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the  
United States Postal Service as first class mail in an  
envelope addressed to: Commissioner for Patents, Box  
1450, Alexandria, VA 22313-1450.

November 7, 2005  
Date of Deposit

Lisa B. Kole  
Attorney Name  
  
Signature

35,225  
Registration No.  
November 7, 2005  
Date of Signature

Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, Applicants respectfully request that the  
documents listed below and on the accompanying PTO 1449 be considered by the Examiner and  
made of record in the above-referenced application. Copies of the listed documents are enclosed.

71. Kaji M et al., 2005, "A side effect of neuraminidase inhibitor in a patient with  
liver cirrhosis," J. Infect. Chemother. 11:41-43.

72. Amaya MF et al., 2004, "Structural insights into the catalytic mechanism of  
*Trypanosoma cruzi* trans-sialidase," Structure 12:775-784.


73. Higuchi ML et al., 2004, "*Trypanosoma cruzi* trans-sialidase as a new therapeutic tool in the treatment of chronic inflammatory diseases: possible action against mycoplasma and chlamydia," Medical Hypothesis 63:616-623.
74. Higuchi ML et al., 2003, "Coinfection with *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in ruptured plaques associated with acute myocardial infarction," Arq. Bras. Cardiol. 81(1):12-22.
75. Higuchi ML et al., 2003, "Pathophysiology of the heart in Chagas' disease: current status and new developments," Cardiovasc. Res. 60: 96- 107.
76. Watts AG et al., 2003, "*Trypanosoma cruzi* trans-sialidase operates through a covalent sialyl-enzyme intermediate:tyrosine is the catalytic nucleophile," J. Am. Chem. Soc. 9(25): 7532-7533.
77. Aiello VD et al., 2002, "A possible role for complement in the pathogenesis of chronic chagastic cardiomyopathy," J. Pathol. 197:224-229.
78. Buschiazzi et al., 2002, "The crystal structure and mode of action of trans-sialidase, a key enzyme in *Trypanosoma cruzi* pathogenesis," Molecular Cell 10:757-768.
79. Dallo SF et al., 2000, "Intracellular DNA replication and long-term survival of pathogenic mycoplasmas," Microb. Pathog 29:301-309.
80. Palomino AS et al., 2000, "Systematic mapping of hearts from chronic chagasic patients: the association between the occurrence of histopathological lesions and *Trypanosoma cruzi* antigens," Ann. Trop. Med. Parasitol. 94(6):571-579.
81. Treanor JJ et al., 2000, "Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. U.S. oral neuraminidase study group," JAMA 283(8):1016-1024.

82. Monto AS et al., 1999, "Efficacy and safety of the neuraminidase inhibitor Zanamivir in the treatment of influenza A and B virus infections." J. Infect. Dis. 180: 254-261.
83. Higuchi ML et al., 1997, "Association of an increase in CD8+ T cells with the presence of *Trypanosoma cruzi* antigens in chronic, human chagasic myocarditis," Am. J. Trop. Med. Hyg. 56:485-489.
84. Higuchi ML et al., 1987, "The role of active myocarditis in the development of heart failure in chronic Chagas' disease: a study based on endomyocardial biopsies," Clin. Cardiol. 10:665-670.
85. Libby P et al., 1986, "A neuraminidase from *Trypanosoma cruzi* removes sialic acid from the surface of myocardial and endothelial cells, " J. Clin. Invest. 77:127-135.
86. Sobeslavsky O. et al., 1968, "Adsorption of *Mycoplasma pneumoniae* to neuraminic acid receptors of various cells and possible role in virulence." J. Bacteriol. 96(3):695-705.

Citation of these references is not an admission that any one is prior art against the present invention.

Please charge the fee due for this submission to Deposit Account No. 02-4377. A copy of this paper is enclosed.


Respectfully submitted,  
BAKER BOTTS L.L.P.



Lisa B. Kole

PTO Reg. No. 35,225

212-408-2628

<b>Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  	Atty. Docket No. 068528.0103	Serial No. 10/086,913
	Applicant: Higuchim, et al.	
	Filing Date March 1, 2002	Group 1652
	Examiner: Maryann Monshipouri	

### U.S. PATENT DOCUMENTS

*Exam. Initial.	No.		Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.

### FOREIGN PATENT DOCUMENTS

Exam Initial	No.		Document No.	Date	Country	Class	Subclass	Translation Yes No


Exam Initial	No.		OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	71		"A Side effect of neuraminidase inhibitor in a patient with liver cirrhosis" by Kaji, et al. <u>J. Infect. Chemother.</u> (2005)(11:41-43)
	72		"Structural Insights into the catalytic mechanism of Trypanosoma cruzi trans-sialidase" by Amaya, et al., <u>Structure</u> , Vol. 12, pp. 775-784, May 2004
	73		"Trypanosoma cruzi trans-sialidase as a new therapeutic tool in the treatment of chronic inflammatory diseases: possible action against mycoplasma and chlamydia" by Higuchi, <u>Medical Hypotheses</u> (2004)(63, 616-623).

533284

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. 068528.0103	Serial No. 10/086,913
<b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b> (Use several sheets if necessary) 	Applicant: Higuchim, et al.	
	Filing Date March 1, 2002	Group 1652
	Examiner: Maryann Monshipouri	


Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	74	"Coinfection with mycoplasma pneumoniae and chlamydia pneumoniae in ruptured plaques associated with acute myocardia infarction" by Higuchi, et al., Arq. Bras Cardiol, Vol. 81, No. 1, 12-22, 2003.
	75	"Pathophysiology of the heart in chagas' disease: current status and new developments" by Higuchi, et al., 2003 European Society of Cardiology, pp. 96-107
	76	"Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: Tryosine is the catalytic nucleophile" by Watts, et al., J. Am. Chem. Soc. 2003, 125, 7532-7533.
	77	A possible role for complement in the pathogenesis of chronic chagasic cardiomyopathy" by Aiello, et al., Journal of Pathology, 2002, 197; 224-229
	78	The Crystal Structure and Mode of Action of Trans-sialidase, a key enzyme in trypanosoma cruzi pathogenesis by Buschiazzo, et al., Molecular Cell, Vol. 10, 757-758, Oct. 2002
	79	Intracellular DNA replication and long term survival of pathogenic mycoplasmas" by Dallo, et al., Microbial Pathogenesis, 2000, 29: 301-309
	80	Systematic mapping of hearts from chronic chagasic patients: the association between the occurrence of histopathological lesions and Trypanosoma cruzi antigens" by Palomino, et al., Annals of Tropical Medicine and Parasitology, Vol. 94, No. 6, 571-579 (2000).
	81	Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza by Treanor, et al., JAMA, Feb. 23, 2000, Vol. 283
	82	Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the treatment of Influenza A and B Virus Infections by Monto, et al., Journal of Infectious Diseases, 1999: 180; 254-61.
	83	Association of an increase in CD8+ T cells with the presence of trypanosoma cruzi antigens in chronic human chagasic mycoarditis by Higuchi, et al., Am. J.Trop. Med. Hyg., 56(5), 1997, pp. 485-489

533284

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. 068528.0103	Serial No. 10/086,913
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	Applicant: Higuchim, et al.	
	Filing Date March 1, 2002	Group 1652
	Examiner: Maryann Monshipouri	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	84	The role of active myocarditis in the development of heart failure in chronic chagas disease : a study based on endomyocardial biopsies by Highuci, et al., Clin. Cardiol. 10, 665-670 (1987)
	85	A Neuraminidase from Trypanosoma cruzi removes sialic acid from the surface of mammalian myocardial and endothelial cells by Libby, et al., J. Clin. Invest., Vol. 77, Jan. 1986, 127-135
	86	Adsorption of Mycoplasma pneumonia to neuraminic acid receptors of various cells and possible role in virulence by Sobeslavsky, et al. Journal of Bacteriology, Sept. 1968, p. 695-705.

533284

Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.